Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States

被引：0
|
作者：
Shujing Zhang
Arielle G. Bensimon
Ruifeng Xu
Ruixuan Jiang
Alexandra Greatsinger
Adina Zhang
Mizuho Fukunaga-Kalabis
Clemens Krepler
机构：
[1] Merck & Co.,
[2] Inc.,undefined
[3] Analysis Group,undefined
[4] Inc.,undefined
来源：
Advances in Therapy | 2023年 / 40卷
关键词：
Adjuvant treatment; Cost-effectiveness analysis; Pembrolizumab; Stage IIB–IIC melanoma; US health sector perspective;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3038 / 3055
页数：17
相关论文
共 50 条
  • [11] Cost-Effectiveness of Pembrolizumab for the Adjuvant Treatment of Melanoma Patients with Lymph Node Involvement Who Have Undergone Complete Resection in Argentina
    Wurcel, Victoria
    Scherrer, Emilie
    Aguiar-Ibanez, Raquel
    Altuna, Juan Ignacio
    Carabajal, Fernando
    Jain, Shrishti
    Baluni, Gargi
    ONCOLOGY AND THERAPY, 2021, 9 (01) : 167 - 185
  • [12] Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
    Min Huang
    Peter A. Fasching
    Amin Haiderali
    Weiguang Xue
    Chelsey Yang
    Wilbur Pan
    Zheng-Yi Zhou
    Peter Hu
    Mitashri Chaudhuri
    Celine Le Bailly De Tilleghem
    Nicolas Cappoen
    Joyce O’Shaughnessy
    Advances in Therapy, 2023, 40 : 1153 - 1170
  • [13] Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
    Huang, Min
    A. Fasching, Peter
    Haiderali, Amin
    Xue, Weiguang
    Yang, Chelsey
    Pan, Wilbur
    Zhou, Zheng-Yi
    Hu, Peter
    Chaudhuri, Mitashri
    De Tilleghem, Celine Le Bailly
    Cappoen, Nicolas
    O'Shaughnessy, Joyce
    ADVANCES IN THERAPY, 2023, 40 (03) : 1153 - 1170
  • [14] Cost-effectiveness analysis of pembrolizumab vs. chemotherapy as second-line treatment for advanced esophageal carcinoma in the United States
    Hu, Jia
    Ye, Zhuomiao
    Xu, Zhe
    Hao, Zhinan
    Wang, Yongjun
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [15] Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States
    Liu, Maobai
    Han, Sijie
    Zheng, Bin
    Cai, Hongfu
    Yang, Jing
    Zhuang, Qian
    Li, Na
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9483 - 9493
  • [16] Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States
    Chen, Jing Voon
    Klein, Timothy M.
    Nesheim, Jeffrey
    Mudd, Paul N., Jr.
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1092 - 1100
  • [17] Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
    Huo, Gengwei
    Song, Ying
    Liu, Wenjie
    Cao, Xuchen
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [18] Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal
    Miguel, Luis Silva
    Lopes, Francisca Vargas
    Pinheiro, Bernardete
    Wang, Jingshu
    Xu, Ruifeng
    Pellissier, James
    Laires, Pedro Almeida
    VALUE IN HEALTH, 2017, 20 (08) : 1065 - 1073
  • [19] Cost-effectiveness of pembrolizumab as an adjuvant treatment of renal cell carcinoma post-nephrectomy in Switzerland
    Schur, Nadine
    Favre-Bulle, Andrea
    Flori, Michael
    Xiao, Ying
    Lupatsch, Judith E.
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1389 - 1397
  • [20] Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States
    Garrison, Louis P., Jr.
    Babigumira, Joseph
    Tournier, Clement
    Goertz, Hans-Peter
    Lubinga, Solomon J.
    Perez, Edith A.
    VALUE IN HEALTH, 2019, 22 (04) : 408 - 415
12345